The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature

References

• Blanco I, Diego I, Bueno P, et al. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. Int J Chron Obstruct Pulmon Dis. 2018;13:57.
   PubMed Web of Science ®Google Scholar
• Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet. 2007;370(9589):741–750.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
   PubMed Web of Science ®Google Scholar
• May SM, Li JT. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy and asthma proceedings. 2015 Jan-Feb;36(1):4–10.
   Google Scholar
• Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. 2019. Report.  [cited 2019 Sept 20]. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf
   Google Scholar
• Ur Rehman A, Hassali MAA, Abbas S, et al. Pharmacological and non-pharmacological management of COPD; limitations and future prospects: a review of current literature. J Public Health. 2019;1–10 [In press].
   Google Scholar
• Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. CEOR. 2013;5:235.
   Google Scholar
• Rehman Au, Hassali MAA, Muhammad SA, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature [journal article]. Eur J Health Econ. 2019 September 28.
   Google Scholar
• de Oca MM, Aguirre C, Varela MVL, et al. exacerbations and health care resource utilization in patients with airflow limitation diseases attending a primary care setting: the PUMa study. Int J Chron Obstruct Pulmon Dis. 2016;11:3059.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2197–2223.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–637.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
   Google Scholar
• Larg A, Moss JR. Cost-of-illness studies. Pharmacoeconomics. 2011;29(8):653–671.
   PubMed Web of Science ®Google Scholar
• Ke X, Marvel J, Yu T-C, et al. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1689.
   PubMed Web of Science ®Google Scholar
• Pasquale MK, Sun SX, Song F, et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Patel J, D’Souza A, et al. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Spec Pharm. 2015;21(7):575–583.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Shah M, D’Souza AO, et al. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med. 2011;105(3):454–460.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Roberts MH, Petersen H, et al. Economic burden of chronic bronchitis in the United States: a retrospective case-control study. Int J Chron Obstruct Pulmon Dis. 2011;6:73.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341.
   PubMedGoogle Scholar
• Perera PN, Armstrong EP, Sherrill DL, et al. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–141.
   PubMedGoogle Scholar
• D’Souza AO, Shah M, Dhamane AD, et al. Clinical and economic burden of COPD in a medicaid population. COPD. 2014;11(2):212–220.
   PubMedGoogle Scholar
• Dhamane AD, Moretz C, Zhou Y, et al. COPD exacerbation frequency and its association with health care resource utilization and costs. Int J Chron Obstruct Pulmon Dis. 2015;10:2609.
   PubMed Web of Science ®Google Scholar
• AbuDagga A, Sun SX, Tan H, et al. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:175.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Petersen NJ, Yu H-J, et al. Burden of COPD in a government health care system: a retrospective observational study using data from the US veterans affairs population. Int J Chron Obstruct Pulmon Dis. 2010;5:125.
   PubMedGoogle Scholar
• Karl FM, Holle R, Bals R, et al. Costs and health-related quality of life in alpha-1-antitrypsin deficient COPD patients. Respir Res. 2017;18(1):60.
   PubMed Web of Science ®Google Scholar
• Menn P, Heinrich J, Huber RM, et al. Direct medical costs of COPD–an excess cost approach based on two population-based studies. Respir Med. 2012;106(4):540–548.
   PubMed Web of Science ®Google Scholar
• Wacker M, Jörres R, Schulz H, et al. Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46.
   PubMed Web of Science ®Google Scholar
• Byng D, Lutter JI, Wacker ME, et al. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. Int J Chron Obstruct Pulmon Dis. 2019;14:1423.
   PubMed Web of Science ®Google Scholar
• Stafyla E, Geitona M, Kerenidi T, et al. The annual direct costs of stable COPD in Greece. Int J Chron Obstruct Pulmon Dis. 2018;13:309.
   PubMed Web of Science ®Google Scholar
• Souliotis K, Kousoulakou H, Hillas G, et al. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2017;12:1395.
   PubMed Web of Science ®Google Scholar
• Geitona M, Hatzikou M, Steiropoulos P, et al. The cost of COPD exacerbations: a university hospital–based study in Greece. Respir Med. 2011;105(3):402–409.
   PubMed Web of Science ®Google Scholar
• Ozkaya S, Findik S, Atici AG. The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease. CEOR. 2011;3:15.
   Google Scholar
• Örnek T, Tor M, Altın R, et al. Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int J Med Sci. 2012;9(4):285.
   PubMed Web of Science ®Google Scholar
• Varol Y, Varol U, Başer Z, et al. The cost of COPD exacerbations managed in hospital. Turk Thorac J. 2013;14(1):19–23.
   Google Scholar
• Kallaru H, Nagasubramanian VR, Balakrishnan HP, et al. Impact of severity of the disease on cost of illness and quality of life of patients with chronic obstructive pulmonary disease. J Young Pharm. 2015;7(2):106.
   Web of Science ®Google Scholar
• Veettil SK, Salmia M, Rajiah K, et al. Cost of acute exacerbation of COPD in patients attending government hospital in Kerala, India. Alcoholism. 2012;30(30):55–58.
   Google Scholar
• Patel KD, Lalwani T, Shah K. Economic burden in direct cost of chronic obstructive pulmonary disease at a tertiary care teaching hospital: a prospective observational cohort study. Indian J Pharm Pract. 2014;7(3):61.
   Google Scholar
• Lisspers K, Larsson K, Johansson G, et al. Economic burden of COPD in a Swedish cohort: the ARCTIC study. Int J Chron Obstruct Pulmon Dis. 2018;13:275.
   PubMed Web of Science ®Google Scholar
• Jansson S-A, Backman H, Stenling A, et al. Health economic costs of COPD in Sweden by disease severity–has it changed during a ten years period? Respir Med. 2013;107(12):1931–1938.
   PubMed Web of Science ®Google Scholar
• Jensen MB, Fenger-Gron M, Fonager K, et al. Chronic obstructive pulmonary disease involves substantial health-care service and social benefit costs. Dan Med J. 2013;60(1):A4557.
   PubMed Web of Science ®Google Scholar
• Løkke A, Hilberg O, Tønnesen P, et al. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998–2010. BMJ Open. 2014;4(1):e004069.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Bonadiman L, Turco P, et al. Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update. CEOR. 2015;7:153.
   Google Scholar
• Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PloS One. 2014;9(6):e101228.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang N, Chen Y, et al. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis. 2016;11:2625.
   PubMed Web of Science ®Google Scholar
• Lou P, Zhu Y, Chen P, et al. Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study. BMC Public Health. 2012;12(1):287.
   PubMed Web of Science ®Google Scholar
• Nielsen R, Johannessen A, Omenaas ER, et al. Excessive costs of COPD in ever-smokers. A longitudinal community study. Respir Med. 2011;105(3):485–493.
   PubMed Web of Science ®Google Scholar
• Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65.
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Lazic Z, Verhaeghe N, et al. Direct medical costs of COPD diagnosis and treatment, Eastern vs. Western European country: examples of Serbia and Belgium. Farmeconomia, Health Econ Ther Pathways. 2013;14(4):161–168.
   Google Scholar
• Pavlovic R, Stojkov S, Binakaj Z. Costs of treatment of severe COPD exacerbation in Serbia. Serb J ExpClin Res. 2018.
   Google Scholar
• Merino M, Villoro R, Hidalgo-Vega Á, et al. social economic costs of COPD in extremadura (spain): an observational study. Int J Chron Obstruct Pulmon Dis. 2018;13:2501.
   PubMed Web of Science ®Google Scholar
• Torabipour A, Hakim A, Angali KA, et al. Cost analysis of hospitalized patients with chronic obstructive pulmonary disease: a state-level cross-sectional study. Tanaffos. 2016;15(2):75.
   PubMedGoogle Scholar
• Kim C, Yoo K, Rhee C, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis. 2014;18(6):737–743.
   PubMed Web of Science ®Google Scholar
• Teo WS, Tan WS, Chong WF, et al. Economic burden of chronic obstructive pulmonary disease. Respirology. 2012 Jan;17(1):120–126.
   PubMed Web of Science ®Google Scholar
• Kayyali R, Odeh B, Frerichs I, et al. COPD care delivery pathways in five European Union countries: mapping and health care professionals’ perceptions. Int J Chron Obstruct Pulmon Dis. 2016;11:2831.
   PubMed Web of Science ®Google Scholar
• Mulpuru S, McKay J, Ronksley PE, et al. Factors contributing to high-cost hospital care for patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:989.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
   PubMed Web of Science ®Google Scholar
• Sen E, Guclu SZ, Kibar I, et al. Adherence to GOLD guideline treatment recommendations among pulmonologists in Turkey. Int J Chron Obstruct Pulmon Dis. 2015;10:2657.
   PubMed Web of Science ®Google Scholar
• Sehl J, O’Doherty J, O’Connor R, et al. Adherence to COPD management guidelines in general practice? A review of the literature. J Ir Coll Physicians Surg. 2018;187(2):403–407.
   Google Scholar
• Shah S, Abbas G, Hanif M, et al. Increased burden of disease and role of health economics: Asia-pacific region. Expert review of pharmacoeconomics & outcomes research. 2019;19(5):517–528.
   Google Scholar